AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10080412 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol and Metoprolol
Number of subjects: 368
Study 8006281 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus aspirin (150 mg once daily)
Number of subjects: 285
Study 8006281 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 285
Study 8006281 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient myocardial ischemia presence
Number of subjects: 285
Study 8006281 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission therapy with aspirin
Number of subjects: 285
Study 2514151 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing with different gas mixtures or after hyperventilation
Number of subjects: 16
Study 801570 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin (Trasylol)
Number of subjects: 30
Study 801570 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 31195706 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch‐ and sucrose‐reduced diet (SSRD) for 2 weeks
Number of subjects: 105
Study 31195706 — intervention group
Group type: COMPARATOR
Intervention: Ordinary eating habits (Control)
Number of subjects: 105
Study 28170396 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 152
Study 28170396 — intervention group
Group type: COMPARATOR
Intervention: Conventional drugs
Number of subjects: 152
Study 26173521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic Stressors (IS)
Number of subjects: 109
Study 26173521 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic Stressors (ES)
Number of subjects: 109
Study 23767174 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (100 mg/kg/min) with remifentanil (0.25 mg/kg/min)
Number of subjects: 100
Study 23767174 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.8% end‐tidal) with remifentanil (0.25 mg/kg/min)
Number of subjects: 100
Study 21923601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol sulfate 2.5 mg diluted in 3 ml of normal saline
Number of subjects: 17
Study 21923601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 ml of normal saline)
Number of subjects: 17
Study 18326600 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT oil (18-24 g/d)
Number of subjects: 49
Study 18326600 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 49
Study 16507194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anaesthesia group (1 mL kg‐1 of caudal-epidural bupivacaine 0.25%)
Number of subjects: 26
Study 16507194 — intervention group
Group type: COMPARATOR
Intervention: Balanced anaesthesia group (5 microg kg‐1 of intravenous fentanyl)
Number of subjects: 26
Study 16507194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anaesthesia group
Number of subjects: 26
Study 16507194 — intervention group
Group type: COMPARATOR
Intervention: Balanced anaesthesia group
Number of subjects: 26
Study 12865041 — intervention group
Group type: EXPERIMENTAL
Intervention: ARDFP+standard‐ART
Number of subjects: 1700
Study 12865041 — intervention group
Group type: EXPERIMENTAL
Intervention: ARDFP+mega‐ART
Number of subjects: 1700
Study 12865041 — intervention group
Group type: COMPARATOR
Intervention: no ARDFP+standard‐ART
Number of subjects: 1700
Study 12865041 — intervention group
Group type: COMPARATOR
Intervention: no ARDFP+mega‐ART
Number of subjects: 1700
Study 11007389 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured silicone gel implants
Number of subjects: 53
Study 11007389 — intervention group
Group type: COMPARATOR
Intervention: Smooth silicone gel implants
Number of subjects: 53
Study 8686202 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6-0.7 g/kg/day) and enalapril (2-10 mg/day)
Number of subjects: 38
Study 8263317 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20-30 mg
Number of subjects: 135
Study 8263317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 2872174 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 7
Study 2872174 — intervention group
Group type: COMPARATOR
Intervention: Brief psychotherapy
Number of subjects: 7
Study 30358715 — intervention group
Group type: EXPERIMENTAL
Intervention: 25‐mug 17beta‐estradiol vaginal tablets (Vagifem)
Number of subjects: 159
Study 30358715 — intervention group
Group type: COMPARATOR
Intervention: 1.25‐mg conjugated equine estrogen vaginal cream (Premarin Vaginal Cream)
Number of subjects: 159
Study 27501505 — intervention group
Group type: COMPARATOR
Intervention: S-1 alone
Number of subjects: 309
Study 27501505 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus LNT
Number of subjects: 309
Study 23588484 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (exercise intervention) 3 times per week for 8 weeks before TKA
Number of subjects: 31
Study 23588484 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prehabilitation)
Number of subjects: 31
Study 22409735 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visit
Number of subjects: 459
Study 22409735 — intervention group
Group type: EXPERIMENTAL
Intervention: Four weekly multiprofessional senior group meetings with one follow-up home visit
Number of subjects: 459
Study 22409735 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 459
Study 20580740 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention program
Number of subjects: 33
Study 20580740 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study 18602429 — intervention group
Group type: EXPERIMENTAL
Intervention: High LC n-3 FA (>1300 mg/day)
Number of subjects: 233
Study 18602429 — intervention group
Group type: COMPARATOR
Intervention: Low LC n-3 FA (<260 mg/day)
Number of subjects: 233
Study 15908621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever exclusively breast fed
Number of subjects: 2192
Study 15908621 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast fed for more than six months
Number of subjects: 2192
Study 15908621 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breast feeding
Number of subjects: 2192
Study 12460152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice and individualized weight management advice for overweight patients (43 patients)
Number of subjects: 84
Study 12460152 — intervention group
Group type: COMPARATOR
Intervention: Usual care (42 patients)
Number of subjects: 84
Study 10520385 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with morphine intravenously by a PCA Plus Micro Delivery Device for at least 48 hours
Number of subjects: 0
Study 10520385 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered intravenous morphine followed by oral acetaminophen with or without codeine in 24 to 36 hours
Number of subjects: 0
Study 7492860 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake (dietary plus supplemental)
Number of subjects: 41
Study 7492860 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 41
Study 1935862 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandocal containing 1 g of effervescent calcium
Number of subjects: 35
Study 1935862 — intervention group
Group type: EXPERIMENTAL
Intervention: Calsup containing 1 g of calcium as the carbonate
Number of subjects: 35
Study 1935862 — intervention group
Group type: EXPERIMENTAL
Intervention: Caltrate containing 1.2 g of calcium as the carbonate
Number of subjects: 35
Study 7042111 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg thrice daily
Number of subjects: 60
Study 7042111 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 400 mg thrice daily
Number of subjects: 60
Study 7042111 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (both dosages)
Number of subjects: 60
Study 7042111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31078459 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital breast tomosynthesis
Number of subjects: 28749
Study 31078459 — intervention group
Group type: COMPARATOR
Intervention: Digital mammography
Number of subjects: 28749
Study 30053956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI; 100/25 or 200/25 μg)
Number of subjects: 423
Study 30053956 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA)
Number of subjects: 423
Study 30053956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 423
Study 26536441 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspen collar
Number of subjects: 48
Study 26536441 — intervention group
Group type: EXPERIMENTAL
Intervention: Miami J standard collar
Number of subjects: 48
Study 26536441 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspen Vista collar
Number of subjects: 48
Study 26536441 — intervention group
Group type: EXPERIMENTAL
Intervention: Miami J Advanced collar
Number of subjects: 48
Study 26536441 — intervention group
Group type: COMPARATOR
Intervention: No collar
Number of subjects: 48
Study 25274615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 5 mg/kg with WBRT (30 Gy/15 fractions/3 weeks)
Number of subjects: 19
Study 25274615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg with WBRT (30 Gy/15 fractions/3 weeks)
Number of subjects: 19
Study 25274615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg with WBRT (30 Gy/10 fractions/2 weeks)
Number of subjects: 19
Study 25274615 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (Bevacizumab combined with WBRT)
Number of subjects: 19
Study 21170682 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Attention Condition (HEAC)
Number of subjects: 141
Study 21170682 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Counseling Intervention (TIP-C)
Number of subjects: 141
Study 19647405 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive coronary flow reserve (CFR) assessment using intravenous adenosine infusion
Number of subjects: 55
Study 19647405 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive coronary flow reserve (CFR) assessment
Number of subjects: 55
Study 19647405 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR cutoff value of 1.7
Number of subjects: 55
Study 17284138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole 9.75 mg
Number of subjects: 357
Study 17284138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole 5.25 mg
Number of subjects: 357
Study 17284138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole 15 mg
Number of subjects: 357
Study 17284138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol 7.5 mg
Number of subjects: 357
Study 17284138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 16036077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study 16036077 — intervention group
Group type: COMPARATOR
Intervention: One specific HRT regimen from the Women's Health Initiative
Number of subjects: 0
Study 12571942 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibutyl phthalate
Number of subjects: 143
Study 12571942 — intervention group
Group type: COMPARATOR
Intervention: New fumanling cream
Number of subjects: 143
Study 9701104 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention
Number of subjects: 196
Study 9701104 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study 7881859 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial insoles (furagin, nitrofurilacroleine, polyhexamethylene guanidine) applied for 2 weeks
Number of subjects: 32
Study 3065158 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) (n = 48)
Number of subjects: 189
Study 3065158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment (ICT) (n = 41)
Number of subjects: 189
Study 3065158 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT) (n = 28)
Number of subjects: 189
Study 31782347 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized ICT training program for older adults
Number of subjects: 85
Study 29987919 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 5081
Study 25963381 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group
Number of subjects: 336
Study 25963381 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone group
Number of subjects: 336
Study 25963381 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 336
Study 25591726 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional rotational angiography (3DRA)
Number of subjects: 60
Study 25591726 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoroscopic views (SFV)
Number of subjects: 60
Study 23663752 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg BID
Number of subjects: 352
Study 23663752 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 352
Study 23663752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 23663752 — intervention group
Group type: EXPERIMENTAL
Intervention: All apremilast doses
Number of subjects: 352
Study 20954763 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Foundations intervention (a series of eight classes delivered before and after birth)
Number of subjects: 169
Study 20954763 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Foundations intervention
Number of subjects: 169
Study 19192663 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus CIK cell transfusion
Number of subjects: 59
Study 19192663 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 59
Study 16495372 — intervention group
Group type: EXPERIMENTAL
Intervention: APC 1 with Transbond Plus Self‐Etching Primer (TPSEP)
Number of subjects: 120
Study 16495372 — intervention group
Group type: EXPERIMENTAL
Intervention: APC 2 with Transbond Plus Self‐Etching Primer (TPSEP)
Number of subjects: 120
Study 16495372 — intervention group
Group type: COMPARATOR
Intervention: Victory Series (V) brackets with Transbond Plus Self‐Etching Primer (TPSEP)
Number of subjects: 120
Study 16495372 — intervention group
Group type: COMPARATOR
Intervention: Victory Series (V) brackets with 37 percent phosphoric acid
Number of subjects: 120
Study 16495372 — intervention group
Group type: EXPERIMENTAL
Intervention: APC 1, APC 2, and V brackets (all types) for shear rebond strengths
Number of subjects: 120
Study 12958052 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (PHYS) 0.12 microg/minute/kg, 7-hour infusion
Number of subjects: 10
Study 11127567 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clear cornea phacoemulsification and trabecular aspiration
Number of subjects: 27
Study 11127567 — intervention group
Group type: COMPARATOR
Intervention: Clear cornea phacoemulsification alone
Number of subjects: 27
Study 9417492 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium treatment
Number of subjects: 28
Study 9417492 — intervention group
Group type: COMPARATOR
Intervention: Control (no selenium treatment)
Number of subjects: 28
Study 1359681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.i.d.
Number of subjects: 0
Study 1359681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 1359681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study 3472452 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise training for 12 weeks
Number of subjects: 34
Study 31227662 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐AFO
Number of subjects: 16
Study 31227662 — intervention group
Group type: COMPARATOR
Intervention: Shoe walking
Number of subjects: 16
Study 30219886 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year trastuzumab plus chemotherapy (arm A, long)
Number of subjects: 1254
Study 30219886 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 weeks trastuzumab plus chemotherapy (arm B, short)
Number of subjects: 1254
Study 26369284 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid advancement (36 ml/kg/day)
Number of subjects: 200
Study 26369284 — intervention group
Group type: EXPERIMENTAL
Intervention: High initiation (24 ml/kg/day)
Number of subjects: 200
Study 26369284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low initiation (4 ml/kg/day)
Number of subjects: 200
Study 26369284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low advancement (24 ml/kg/day)
Number of subjects: 200
Study 26369284 — intervention group
Group type: EXPERIMENTAL
Intervention: High advancement (36 ml/kg/day)
Number of subjects: 200
Study 24585432 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxilen®
Number of subjects: 18
Study 24585432 — intervention group
Group type: COMPARATOR
Intervention: YSP Amoxicillin® capsule
Number of subjects: 18
Study 22909146 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride topical gel (OTG) 10% applied once daily (1g, 100mg oxybutynin)
Number of subjects: 152
Study 22909146 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release oxybutynin (OXB-IR) 5mg capsule three times/day
Number of subjects: 152
Study 22909146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 20575621 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine 1.3% topical patch (DETP) applied once daily for 7 days
Number of subjects: 274
Study 20575621 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 274
Study 17900227 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 86
Study 17900227 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine Purite 0.15%
Number of subjects: 86
Study 15138297 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 1 mg alone
Number of subjects: 12
Study 15138297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 200 mg twice daily
Number of subjects: 12
Study 15138297 — intervention group
Group type: COMPARATOR
Intervention: FTY720 1 mg with cyclosporine
Number of subjects: 12
Study 15138297 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine with FTY720
Number of subjects: 12
Study 15138297 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 alone and with cyclosporine
Number of subjects: 12
Study 11585480 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly administration of antenatal corticosteroids (betamethasone, 12 mg intramuscularly repeated once in 24 hours for 2 doses every week until 34 weeks' gestation or delivery)
Number of subjects: 502
Study 11585480 — intervention group
Group type: COMPARATOR
Intervention: Single course of antenatal corticosteroids (either betamethasone, 12 mg intramuscularly repeated once in 24 hours for 2 doses, or dexamethasone, 6 mg intramuscularly repeated every 12 hours for 4 doses)
Number of subjects: 502
Study 9664917 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (average American diet) providing 37% of energy from fat, 16% from saturated fatty acids (SFAs)
Number of subjects: 103
Study 9664917 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B (step 1 diet) providing 30% of energy from fat, 9% from SFA
Number of subjects: 103
Study 9664917 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet C (low SFA diet) providing 26% of energy from fat, 5% from SFA
Number of subjects: 103
Study 7656916 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine consumption with dinner
Number of subjects: 8
Study 7656916 — intervention group
Group type: COMPARATOR
Intervention: Mineral water consumption with dinner
Number of subjects: 8
Study 2695152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 1328
Study 2695152 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 1328
Study 855849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subgallate
Number of subjects: 6
Study 855849 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine sulfate
Number of subjects: 6
Study 855849 — intervention group
Group type: EXPERIMENTAL
Intervention: Deodorized tincture of opium (DTO)
Number of subjects: 6
Study 855849 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenoxylate (Lomotil)
Number of subjects: 6
Study 855849 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 6
Study 855849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat excretion
Number of subjects: 6
Study 31780395 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐lungNET
Number of subjects: 173
Study 30707361 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin 50 U
Number of subjects: 33
Study 30707361 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin 100 U
Number of subjects: 33
Study 30707361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 33
Study 30707361 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat Botulinum toxin 100 U injections
Number of subjects: 33
Study 28658172 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric blanket plus forced-air warming system (group EF)
Number of subjects: 346
Study 28658172 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular blanket plus electric blanket (group E)
Number of subjects: 346
Study 28658172 — intervention group
Group type: COMPARATOR
Intervention: Regular blanket (group C)
Number of subjects: 346
Study 26224390 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting stent (PES = Coroflex Please, B.Braun)
Number of subjects: 202
Study 26224390 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS = Coroflex) followed by paclitaxel coated balloon (PCB = Sequent Please, B.Braun)
Number of subjects: 202
Study 26224390 — intervention group
Group type: COMPARATOR
Intervention: BMS + PCB
Number of subjects: 202
Study 24226381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron and metoclopramide (Group II)
Number of subjects: 308
Study 24226381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate and dexamethasone (Group III)
Number of subjects: 308
Study 24226381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron as a single medication (Group IV)
Number of subjects: 308